Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients

Inclusion Criteria: * Able to understand and provide informed consent. * Have received a renal transplant (first or repeat), and the most recent protocol biopsy within 3 months of consent is diagnostic for ABMR or cellular rejection. Clinical Inclusion Criteria: * Stable renal function: * Serum creatinine at the time of surveillance biopsy cannot be \> 15% greater than the serum creatine prior to the biopsy (must be within 3 months of the biopsy); * Estimated eGFR \> 30 ml/min by MDRD. Histologic Criteria for Eligibility: * ABMR: microvascular inflammation scores for glomerulitis (g) and peritubular capillaritis (ptc) (g:1 or 2; ptc:1 or 2). * Cellular rejection: tubulitis (t) (t:1or 2); interstitial inflammation (i) (i:1 or 2); intimal arteritis (v) (v: 1 or 2). * Mixed ABMR and cellular rejection. Exclusion Criteria: * Nephrotic range proteinuria (≥ 3.5g/24h), detected more than once in the year preceding screening. * History of post-transplant intervention for obstructive uropathy * One or more of the following laboratory values: o Hemoglobin (Hb} ≤ 8 g/dL, Potassium (K) ≥ 5.5 mEq/dL, Alanine aminotransferase (ALT) ≥ 60 U/L, Hemoglobin A1C (HbA1c) ≥ 7%, International Normalized Ratio (INR) ≥ 2.0, Platelet count \< 50 x 109/L (patients who receive a platelet transfusion to increase their platelet count will not be excluded). * One or more of the following parameters: o Temperature ≥ 38°C (100.4°F), Respiratory rate ≥ 20/min, Oxygen saturation (SpO2) ≤ 90%, Syst…